An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome

Trial Profile

An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Avacopan (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACCESS
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Mar 2017 Status changed from recruiting to discontinued.
    • 07 Nov 2016 According to ChemoCentryx media release, the company has announced positive data (n=5) from this pilot phase II trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top